Mesoblast Targets Broader Cancer Indications
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from Mesoblast
- Revascor Increases Blood Supply to Damaged Heart Muscle
- Mesoblast Included in S and P/ASX 200 Index
- Key Product Franchises Featured at Nomura Asia Equity Forum
- FDA Clears Phase 2 Trial to Treat Degenerative Disc Disease
- Cardiac Events, Mortality and Hospitalization Reduced
Later from Mesoblast
- Key Bone Repair Patent Granted in the United States
- Market Exclusivity Strengthened by New USA Healthcare Act
- MSB partner jcr files for product approval
- Mesoblast Cells Show Disease Modifying Effects on Knee OA
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast